Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
Background: Fulminant myocarditis has been reported in patients treated with immune checkpoint inhibitors. We present the first described case of acute immune-mediated myocarditis and myositis associated with durvalumab plus tremelimumab combination therapy. The patient was undergoing treatment for...
Main Authors: | Syed S. Mahmood, Carol L. Chen, Natalie Shapnik, Udhay Krishnan, Harsimran S. Singh, Vicky Makker |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-08-01
|
Series: | Gynecologic Oncology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235257891830050X |
Similar Items
-
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
by: Houda Bahig, et al.
Published: (2019-01-01) -
A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
by: Michal Sarfaty, et al.
Published: (2021-02-01) -
Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment
by: Sooraj John, et al.
Published: (2017-07-01) -
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
by: Shuhua Wang, et al.
Published: (2020-07-01) -
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
by: Carol I Geppert, et al.
Published: (2020-07-01)